FibroBiologics discusses its fibroblast-based cell therapy platform for chronic diseases, including DFU, psoriasis, and MS, at an investor webinar.

The exclusive event will feature Pete O'Heeron, CEO, and Jason Davis, CFO, who will provide an overview of FibroBiologics' ...

In the past month, FibroBiologics, Inc. (NASDAQ: FBLG) has disclosed the advancement of its fibroblast therapy platform into additional indications, including: On March 2, 2026, the company announced ...

The Mayo Clinic Tumor Microenvironment Lab is studying ways to determine which types of benign breast disease might turn into cancer.

Human skin is constantly rebuilding itself. Every few weeks, the outermost layers shed and are replaced by new cells pushed up from the base. For decades, scientists believed this renewal depended ...

In a significant breakthrough in inflammatory arthritis research, a study published today (Feb. 23) in Nature Immunology has revealed that inflammation-associated fibroblasts—a type of cell in ...

BACKGROUND: Direct reprogramming of cardiac fibroblasts (CFs) into induced cardiomyocytes (iCMs) holds promise as a ...

Keloids are raised, overgrown scars that can develop after skin injuries or surgery, often extending beyond the original wound boundaries. For many people, keloids are more than just a cosmetic ...

Helmholtz Munich researchers revealed a conserved differentiation process with clinical implications for injury repair, identifying a multipotent fibroblast progenitor in the fascia— the deepest ...

FibroBiologics receives US patent for the therapeutic use of fibroblasts in wound healing: Houston Saturday, September 5, 2026, 11:00 Hrs [IST] FibroBiologics, Inc., a clinical-st ...